top of page

Struggling with multiple UTIs?

The ELIMINATE Study investigates a new approach to removing a specific bacterium known to cause a majority of UTIs

Urinary tract infections (UTIs) are a growing problem 

Worldwide, an estimated 150 million people are affected by Urinary Tract Infections (UTIs) each year.  Approximately 80% of these are caused by Escherichia coli (E. coli), often including difficult-to-treat strains that are resistant to commonly used antibiotics.  Nearly 40% of patients with UTIs experience a recurrence within months of the first episode.  

 

Both the U.S. Centers for Disease Control and Prevention (CDC) and World Health Organization (WHO) have identified antibiotic-resistant E. coli as an urgent and serious public health threat requiring the development of new treatments. 

Who may participate?

Three ladies.png

UTIs affect millions of patients each year regardless of sex. The ELIMINATE Trial is initially studying the safety and efficacy of LBP-EC01 in adult women. â€‹

When you participate in a study, you’re helping find new ways to treat UTIs. Your participation can make a difference.

Condition

Urinary tract infection (UTIs) caused by drug-resistant E. coli

Age

18 - 75 years old

Sex

Female

Each clinical study has its own guidelines for who can participate, called eligibility criteria. However, only the research study staff can determine if you qualify to enroll in the study.

Hear from a patient about her experience

Are you interested in participating in the ELIMINATE Trial?

Complete this short survey to see if you are eligible. 

Phage.png
Phage.png
Phage.png

LBP-EC01 is a clinical-stage precision investigational therapeutic designed to target E. coli infections.  It is a cocktail of bacteriophages (Phages) engineered to precisely remove E. coli bacteria, which may be resistant to multiple drugs, in patients with UTIs.  

LocusBio_Row_Blue_2x.png
bottom of page